SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-059753
Filing Date
2023-11-07
Accepted
2023-11-07 07:02:08
Documents
14
Period of Report
2023-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fulc-20231107.htm   iXBRL 8-K 45772
2 EX-99.1 fulc-ex99_1.htm EX-99.1 133278
3 GRAPHIC img189780767_0.jpg GRAPHIC 2981
  Complete submission text file 0000950170-23-059753.txt   315325

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fulc-20231107.xsd EX-101.SCH 2472
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fulc-20231107_pre.xml EX-101.PRE 10289
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fulc-20231107_lab.xml EX-101.LAB 14018
8 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20231107_htm.xml XML 4925
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 231381503
SIC: 2834 Pharmaceutical Preparations